Celgene to Buy into China’s BeiGene
US biopharmaceutical company Celgene has agreed to buy a stake in China’s BeiGene and help to develop and commercialize that company’s investigational treatment for tumor cancers. read more
View ArticleAlong the Acquisition Trail
For the global specialty chemicals sector, the past two years have been among the most exciting of the young millennium. Many mergers and acquisitions were in the spotlight in 2017 and more have moved...
View ArticleAmgen and China’s BeiGene in Oncology Partnership
US biotech Amgen has agreed to take a 20.5% stake in China’s BeiGene as the two companies enter into a strategic collaboration to develop cancer drugs. The move significantly accelerates Amgen’s plans...
View Article
More Pages to Explore .....
